ArticleBMJ public health2026
Is targeted cytomegalovirus testing of infants feasible in Western Australia? An observational study.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Congenital cytomegalovirus (cCMV) is a common infection at birth with the potential to cause significant and permanent morbidity, most commonly hearing loss. Targeted cCMV testing programmes use hearing loss as an indicator of an infant being at high risk of the infection and thereby can 'target' or focus testing on those at greatest risk. Australian and International guidelines recommend that high-risk infants be offered cCMV testing, yet across Australia, a formal testing system does not exist. This paper presents the results of a Western Australian (WA) targeted testing study, detailing its methodology, strengths and challenges to evaluate the feasibility of a targeted cCMV testing programme in WA. Methods: A 2-year statewide observational study was conducted in WA from 2020 to 2022. The study used the established universal infant hearing-screening programme to identify infants at high risk of cCMV. Infants who failed their newborn hearing test were recruited to the study and underwent saliva PCR testing. Confirmatory testing was via urine PCR for CMV. This study examines the first 12 months of data.Data collected included the timeliness of testing and results, both integral to effective cCMV diagnosis and treatment. The reasons for high-risk infants being ineligible for testing were explored, and for cCMV-positive infants, the timeliness of reviews and investigations was evaluated. Results: During the study period, 212 infants at high risk of cCMV were identified. Of these, 134 (63%) met inclusion criteria and 103 (77%) consented to participate. The study achieved complete and timely cCMV testing, along with timely review and investigation of cCMV-positive infants. Barriers to testing eligibility among high-risk infants (n=78) were assessed to inform strategies to improve testing access. Conclusions: WA currently lacks a structured, targeted cCMV testing programme, resulting in missed diagnosis and early intervention opportunities for high-risk infants. The study findings indicate that a structured, targeted cCMV testing programme is feasible and would ensure affected children receive care that aligns with national and international standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.